Back

Ac-FAPI-04 Promotes Anti-tumor Immunity via IL-27 Activation and Tnfaip3 Inhibition

Jiang, S.; Zhang, S.; Zhang, T.; Tian, H.; Shi, Y.; Gao, X.; Li, S.; Wang,, R.; Hu, K.

2026-01-08 molecular biology
10.64898/2026.01.07.698054 bioRxiv
Show abstract

BackgroundAccumulating evidence substantiates the capacity of targeted radionuclide therapy (TRT) to potentiate tumor immunotherapy responses. However, combining TRT and immunotherapies exhibits substantial varying efficacy, underscoring the importance of investigating mechanisms through which TRT remodels the tumor microenvironment (TME). Despite recent advancements, the specific signaling molecules mediated by TRT that regulate the functions of cytotoxic T lymphocytes (CTLs) remain unclear. MethodsGiven the demonstrated potential of -radionuclides targeting the fibroblast activation protein (FAP) in TRT, this study employed [225Ac]Ac-FAPI-04 to investigate the mechanisms of TRT-induced TME remodeling. The cytotoxic effects were first evaluated in the B16F10 cell line, followed by an assessment of its in vivo therapeutic efficacy in tumor-bearing mice. RNA-sequencing analysis was utilized to elucidate underlying signaling pathways involving immune responses. Results[225Ac]Ac-FAPI-04 significantly induced DNA double-strand breaks, further elevated ROS levels, and apoptosis in tumor cells. Transcriptomic profiling revealed that [225Ac]Ac-FAPI-04 activates the IL-27/JAK-STAT pathway to amplify interferon-mediated responses, indicating IL-27 serves as a critical regulatory signal for CTLs during TRT. A concomitant observation was the downregulation of Tnfaip3 following [225Ac]Ac-FAPI-04 treatment. Tnfaip3 is implicated in modulating CTLs behavior and intratumoral infiltration, while its downregulation was associated with the upregulation of cytotoxic effector molecules, as confirmed in this study. ConclusionThis study identifies a TRT-induced pattern of synergistic signaling mediated by IL-27 and Tnfaip3, which collectively enhances CTL recruitment and potentiates their cytotoxic function. These findings provide a detailed mechanistic rationale for strategies aimed at augmenting the therapeutic efficacy of TRT and immunotherapy combinations.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
Pharmacological Research
18 papers in training set
Top 0.1%
7.9%
2
Journal of Medicinal Chemistry
77 papers in training set
Top 0.2%
7.3%
3
eLife
5828 papers in training set
Top 15%
7.3%
4
International Journal of Molecular Sciences
494 papers in training set
Top 2%
4.9%
5
Acta Biochimica et Biophysica Sinica
23 papers in training set
Top 0.1%
4.4%
6
Acta Pharmaceutica Sinica B
11 papers in training set
Top 0.1%
4.1%
7
FEBS Open Bio
31 papers in training set
Top 0.1%
3.2%
8
The Journal of Pharmacology and Experimental Therapeutics
18 papers in training set
Top 0.1%
2.7%
9
PLOS ONE
5266 papers in training set
Top 42%
2.5%
10
Scientific Reports
3612 papers in training set
Top 43%
2.4%
11
Biomedicine & Pharmacotherapy
42 papers in training set
Top 0.4%
2.4%
12
Redox Biology
70 papers in training set
Top 0.5%
2.4%
50% of probability mass above
13
Journal of Controlled Release
44 papers in training set
Top 0.4%
2.1%
14
Theranostics
37 papers in training set
Top 0.4%
2.0%
15
Molecular Therapy Nucleic Acids
39 papers in training set
Top 0.4%
1.9%
16
Frontiers in Oncology
103 papers in training set
Top 2%
1.7%
17
Cancers
213 papers in training set
Top 3%
1.7%
18
Nature Communications
5641 papers in training set
Top 45%
1.7%
19
iScience
1154 papers in training set
Top 18%
1.7%
20
ACS Chemical Biology
167 papers in training set
Top 2%
1.5%
21
Advanced Science
286 papers in training set
Top 6%
1.3%
22
ChemMedChem
16 papers in training set
Top 0.2%
1.1%
23
Communications Biology
993 papers in training set
Top 21%
1.1%
24
Biomolecules
100 papers in training set
Top 2%
1.1%
25
Neoplasia
23 papers in training set
Top 0.7%
0.9%
26
Cells
249 papers in training set
Top 7%
0.9%
27
Biochimie
25 papers in training set
Top 0.7%
0.9%
28
JNCI: Journal of the National Cancer Institute
19 papers in training set
Top 0.3%
0.9%
29
Molecular Therapy
81 papers in training set
Top 2%
0.6%